Northern Ireland-based digital pathology firm Cirdan has secured a £2.3m investment, led by Kernel Capital through the Bank of Ireland Kernel Capital Growth Fund (NI).
Other investors in the Lisburn firm include Clarendon Fund Managers and high net worth private investors.
Cirdan said the funding will assist in the creation of up to 25 new jobs ahead of new contract wins.
The company has clients in over 150 laboratories and hospitals across 20 countries and six continents.
Stephen Dunniece, Director of Cirdan, thanked the company's investors for their continued support.
"This in addition to securing several new contracts will be used to accelerate our operational expansion and deliver on our strong order book for 2023 and beyond," he added.
"Cirdan is a company on a positive growth trajectory with an excellent product, strong team and blue-chip clients across six continents," commented Denise Sidhu, a Partner at Kernel Capital.
"The company is ideally placed to capitalise on the accelerated shift from traditional patient care to digital pathology which has the potential to revolutionize timely disease diagnosis leading to better and faster patient care," she added.
Niall Devlin, Head of Business Banking at Bank of Ireland UK, said that Cirdan are a great example of an indigenous company delivering innovative and effective solutions that are making a difference for clinicians and patients both locally and internationally.
"We are delighted they have benefited from investment through the Bank of Ireland Kernel Capital Growth Fund, and we look forward to seeing the business further grow and succeed," he added.
